Biosergen
Biosergen publishes interim report for first quarter 2024
REG
Summary of the Interim Report for Q1 2024
| 2024 | 2023 | 2023 | |
| TSEK | Jan-Mar | Jan-Mar | Jan-Dec |
| Profit/loss | |||
| Other income | 693 | 5.315 | 9.378 |
| Profit/loss before depreciation (EBITDA | -6.798 | -5.029 | -27.265 |
| Operating profit/loss before net financials | -6.798 | -5.029 | -27.265 |
| Net financials | -95 | 2 | 228 |
| Netprofit/loss for the period | -6.893 | -5.027 | -27.037 |
| Earnings per share (SEK) | -0,05 | -0,18 | -0,53 |
Highlights during Q1 2024
- March 26, Biosergen announces the outcome in the rights issue.
- March 15, Members of the board of directors and management subscribe in ongoing rights issue
- March 5, Biosergen publishes prospectus due to rights issue of units.
- March 1, Bulletin from the extraordinary general meeting in Biosergen AB (publ).
- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan.
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor.
HIighlights after the period
- April 16, Conversion of paid subscribed units and first day of trading with warrants of series TO3.
- April 9, Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue.
The Financial report can be found on our website: https://biosergen.net/investors/press-releases
| Datum | 2024-05-31, kl 08:30 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.